糖尿病领域研发态势分析

doi:10.16288/j.yczz.22-272

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2022, Vol. 44 ›› Issue (10): 824-839.doi: 10.16288/j.yczz.22-272

• Research Trends • Previous Articles Next Articles

Progress on research and development in diabetes mellitus

Liwen Zhang¹(), Meihua Ruan¹(), Jialan Liu², Caihong He^1,³, Jianrong Yu^1,³()

1. Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China
2. Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China
3. University of Chinese Academy of Sciences, Beijing 100049, China

Received:2022-08-15 Revised:2022-09-30 Online:2022-10-20 Published:2022-10-12
Contact: Yu Jianrong E-mail:zhangliwen@sinh.ac.cn;mhruan@sinh.ac.cn;jryu@sinh.ac.cn
Supported by:
the National Natural Science Foundation of China(L1924031)

Abstract

Abstract:

Diabetes mellitus is a kind of metabolic disease characterized by hyperglycemia resulting from insulin insufficiency and insulin resistance. It has become one of the major diseases threatening human health. In this paper, we analyze the current R&D status of diabetes from the aspects of papers, patents, drugs and industrial development. The results show that scientific outcomes are increasing steadily and the hot topics are diabetic complications and epidemiological research. In terms of technology development, large pharmaceutical companies, such as Janssen Pharmaceutical, Lilly pharmaceutical, Boehringer Ingelheim, are actively engaged in diagnosis, treatment and management of diabetes. By March 23 2022, 207 drugs have been launched and a large number of candidate drugs are in the pre-clinical and clinical stage. In terms of industrial development, the potential diabetes market is huge and the digital management of diabetes is developing rapidly. China has certain strength in diabetes research and development. In the future, measures should be taken to strengthen the transformation of research outcomes, and promote product development to meet China’s huge needs of diabetes cares.

Key words: diabetes mellitus, research status, drug development, industrial development

Liwen Zhang, Meihua Ruan, Jialan Liu, Caihong He, Jianrong Yu. Progress on research and development in diabetes mellitus[J]. Hereditas(Beijing), 2022, 44(10): 824-839.

Figures/Tables 16

Fig. 1

Fig. 2

Table 1

Table 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

Fig. 8

Fig. 9

Table 3

Fig. 10

Fig. 11

Fig. 12

Table 4

References 37

[1]	Endocrine Metabolic Branch of Chinese Medical Doctor Association, National Clinical Medical Research Center for Metabolic Diseases. Classification of diabetes mellitus in China: an expert consensus statement. Chin J Diabetes, 2022, 14(2): 120-139.
	中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心. 糖尿病分型诊断中国专家共识. 中华糖尿病杂志, 2022, 14(2): 120-139.
[2]	International Diabetes Federation.IDF Diabetes Atlas 10th edition. [2022-04-20]. .
[3]	Nature Milestones in Diabetes. (2021-10-29)[2022-03-20]. .
[4]	Ma N, Zhu YN. Pathogenesis and recent research progress of gestational diabetes mellitus. Smart Healthcare, 2019, 5(22): 62-64, 67.
	马宁, 朱永宁. 妊娠期糖尿病的发病机制和最新研究进展. 智慧健康, 2019, 5(22): 62-64, 67.
[5]	Song D, Ran LY, Jiang RJ, Wu YJ.Animal models in diabetes mellitus research. Chin J Comp Med, 2016, 26(9): 83-87.
	宋丹, 冉丽媛, 姜如娇, 吴英杰. 糖尿病研究中的动物模型进展. 中国比较医学杂志, 2016, 26(9): 83-87.
[6]	Marek-Trzonkowska N, Myśliwiec MŁ, Dobyszuk A, Grabowska M, Techmańska I, Juścińskad J, Wujtewicz MA, Witkowski P, Młynarski W, Balcerska A, Myśliwska J, Trzonkowski P. Administration of CD4+ CD25^highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care, 2012, 35(9): 1817-1820. doi: 10.2337/dc12-0038 pmid: 22723342
[7]	Marek-Trzonkowska N, Myśliwiec ML, Dobyszuk A, Grabowska M, Derkowskab I, Juścińskad J, Owczuke R, Szadkowskaf A, Witkowskig P, Młynarskif W, Jarosz- Choboth P, Bossowskii A, Sieberta J, Trzonkowskic P. Therapy of type 1 diabetes with CD4+ CD25^highCD127- regulatory T cells prolongs survival of pancreatic islets— results of one year follow-up. Clin Immunol, 2014, 153(1): 23-30. doi: 10.1016/j.clim.2014.03.016 pmid: 24704576
[8]	Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol, 2017, 5(4): 251-260. doi: 10.1016/S2213-8587(17)30013-X
[9]	Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus, 2021, 13(4): 315-409.
	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版). 中华糖尿病杂志, 2021, 13(4): 315-409.
[10]	El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017, 389(10067): 369-380. doi: S0140-6736(16)32567-3 pmid: 28007348
[11]	Cai C, Jia WP. Application and challenge of artificial intelligence in continuous Diabetes management. Bull Natl Nat Sci Found China, 2021, 35(1): 104-109.
	蔡淳, 贾伟平. 人工智能在糖尿病全程健康管理的应用与挑战. 中国科学基金, 2021, 35(1): 104-109.
[12]	Shen S, Liu HF, Xu XY, Yu JN. Research progress of drugs for Diabetic complication treatment. Chin Pharm Aff, 2012, 26(8): 906-910.
	申升, 刘宏飞, 徐希明, 余江南. 治疗糖尿病并发症药物的研究进展. 中国药事, 2012, 26(8): 906-910.
[13]	Alanazi AZ, Mohany M, Alasmari F, Mothana RAA, Alshehri AOA, Alhazzani K, Ahmed MM, Al-Rejaie SS. Amelioration of diabetes-induced nephropathy by loranthus regularis: implication of oxidative stress, inflammation and hyperlipidaemia. Appl Sci, 2021, 11(10): 4548. doi: 10.3390/app11104548
[14]	Kotova JA, Zuikova AA, Pashko AN, Strahova NV, Krasnorutskaya ON, Shevzova VI, Esina EY. Markers of endothelial damage, inflammation, oxidative and cellular stress in patients with coronary artery disease and type 2 diabetes. Int J Biomed, 2020, 10(2): 104-107. doi: 10.21103/Article10(2)_OA2
[15]	Gupta A, Nayan N, Nair R, Kumar K, Joshi A, Sharma S, Singh J, Kapoor R. Diabetes mellitus and hypertension increase risk of death in novel corona virus patients irrespective of age: a prospective observational study of co-morbidities and COVID-19 from India. SN Compr Clin Med, 2021, 3(4): 937-944. doi: 10.1007/s42399-021-00851-1
[16]	Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes, 2020, 12(12): 895-908. doi: 10.1111/1753-0407.13085
[17]	Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Pediatric Diabetes Consortium. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabet Med, 2020, 37(5): 863-867. doi: 10.1111/dme.14233
[18]	Mobley-Bukstein W, Reece SM, Hebdon K. Special considerations in the management and education of older persons with diabetes. ADCES Pract, 2021, 9(4): 30-42.
[19]	Minschart C, De Weerdt K, Elegeert A, Van Crombrugge P, Moyson C, Verhaeghe J, Vandeginste S, Verlaenen H, Vercammen C, Maes T, Dufraimont E, De Block C, Jacquemyn Y, Mekahli F, De Clippel K, Van Den Bruel A, Loccufier A, Laenen A, Devlieger R, Mathieu C, Benhalima K. Antenatal depression and risk of gestational diabetes, adverse pregnancy outcomes, and postpartum quality of life. J Clin Endocrinol Metab, 2021, 106(8): e3110-e3124. doi: 10.1210/clinem/dgab156 pmid: 33693709
[20]	Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol, 2021, 20(1): 14. doi: 10.1186/s12933-020-01197-z pmid: 33413348
[21]	Math L, Fatima R. Adaptive machine learning classification for diabetic retinopathy. Multimedia Tools Appl, 2021, 80: 5173-5186. doi: 10.1007/s11042-020-09793-7
[22]	McGrail S. Eli Lilly takes on digital diabetes care management. (2021-05-12)[2022-05-15]. .
[23]	Sanofi. A broad range of innovative medicines. (2019- 06-14)[2022-05-13]. .
[24]	Novo Nordisk. R&D pipeline. [2022-05-15]. .
[25]	AstraZeneca. Pipeline. (2022-03-22)[2022-05-15]. .
[26]	通化东宝药业股份有限公司. 企业简介. [2022-05-15]. .
[27]	甘李药业股份有限公司. 企业介绍. [2022-05-15]. .
[28]	联邦制药国际控股有限公司. 集团简介. [2022-05-15]. .
[29]	三生制药. [2022-05-15]. .
[30]	华经情报网.2021-2026 年中国糖尿病药品市场供需现状及投资战略研究报告. (2021-01-12)[2022-06-15]. .
[31]	Yuan S, Gill D, Giovannucci EL, Larsson SC. Obesity type 2 diabetes, lifestyle factors, and risk of gallstone disease: a mendelian randomization investigation. Clin Gastroenterol Hepatol, 2022, 20(3): e529-e537. doi: 10.1016/j.cgh.2020.12.034
[32]	Repple J, König A, de Lange SC, Opel N, Redlich R, Meinert S, Grotegerd D, Mauritz M, Hahn T, Borgers T, Leehr EJ, Winter N, Goltermann J, Enneking V, Fingas SM, Lemke H, Waltemate L, Dohm K, Richter M, Mehler DMA, Holstein V, Gruber M, Nenadic I, Krug A, Brosch K, Schmitt S, Stein F, Meller T, Jansen A, Steinsträter O, Amare AT, Kircher T, Baune BT, van den Heuvel MP, Dannlowski U. Association between genetic risk for type 2 diabetes and structural brain connectivity in major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging, 2022, 7(3): 333-340.
[33]	Cinkajzlová A, Mráz M, Haluzík M. Adipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases. J Endocrinol, 2021, 252(1): R1-R22. doi: 10.1530/JOE-21-0159
[34]	华经情报网.2020年糖尿病药物行业现状及趋势分析, 降糖药物将加快升级换代. (2021-09-09)[2022-03-24]. .
[35]	Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet, 2022, 399(10322): 394-405. doi: 10.1016/S0140-6736(21)01919-X
[36]	Guo LX. 2021 annual review of major progress in diabetes. Chin J Diabetes Mellitus, 2022, 14(1): 1-8.
	郭立新. 2021年糖尿病领域年度重大进展回顾. 中华糖尿病杂志, 2022, 14(1): 1-8.
[37]	动脉网. 智能设备成为糖尿病数字化管理基本前提, 关键创新点有哪些?(2021-01-06)[2022-03-24]. .

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

国家	论文量(篇)	ESI高水平论文量(篇)	ESI高水平论文量占比
美国	48518	1371	2.83%
中国	35710	425	1.19%
英国	14764	634	4.29%
意大利	9679	343	3.54%
德国	9608	340	3.54%
日本	9256	145	1.57%
澳大利亚	8597	292	3.40%
加拿大	7945	291	3.66%
印度	7758	150	1.93%
韩国	7193	107	1.49%

国际机构	论文量(篇)	ESI高水平论文量(篇)	ESI高水平论文量占比	中国机构	论文量(篇)	ESI高水平论文量(篇)	ESI高水平论文量占比
哈佛大学	5714	356	6.23%	上海交通大学	2090	42	2.01%
多伦多大学	2469	146	5.91%	首都医科大学	1529	26	1.70%
哥本哈根大学	2424	112	4.62%	北京大学	1454	31	2.13%
约翰·霍普金斯大学	2234	100	4.48%	中山大学	1434	39	2.72%
悉尼大学	1992	105	5.27%	中国医学科学院北京协和医院	1386	22	1.59%
卡罗林斯卡研究所	1894	80	4.22%	中国科学院	1349	28	2.08%
伦敦大学学院	1828	120	6.56%	复旦大学	1299	34	2.62%
密歇根大学	1692	81	4.79%	南京医科大学	1259	8	0.64%
巴黎大学	1685	92	5.46%	华中科技大学	1215	32	2.63%
伦敦帝国理工学院	1594	134	8.41%	中南大学	1166	18	1.54%

国际公司	药物数量	国内机构	药物数量
礼来公司	50	通化东宝药业股份有限公司	13
赛诺菲公司	45	正大天晴药业集团有限公司	12
诺和诺德公司	32	中国科学院上海药物研究所	9
阿斯利康公司	30	江苏恒瑞医药股份有限公司	7
辉瑞公司	28	天士力医药集团股份有限公司	7
默克公司	25	甘李药业股份有限公司	6
武田制药公司	25	深圳信立泰药业股份有限公司	6
强生公司	24	华东医药股份有限公司	5
诺华公司	19	宜昌东阳光长江药业股份有限公司	5
勃林格殷格翰公司	17	三生制药集团	4
		中国药科大学	4
		深圳君圣泰生物技术有限公司	4
		珠海联邦制药有限公司	4

公司简称	所在地	轮次	融资时间	金额	投资机构
智云健康	浙江	C+轮、D轮	2020年	10亿元	SIG、中电数据、三星电子、东英金融、招银国际、天士力、博将资本、LB资本
		C轮	2019年	1亿美元	LB资本、IDG、美年大健康、中金资本、中电健康产业基金、天力士、中国平安、三星资本
		B2轮	2018年	1亿元	天亿投资集团
		B1轮	2017年	过亿元	经纬创投、基石资本、IDG和平安创投
		A轮	2015年	1500万美元	IDG、经纬中国、平安创投、某战略投资机构
掌控糖尿病	福建	B轮	2017年	1000万元	未公开
		A轮	2015年	6000万元	光信资本、尚势资本
		天使轮	2013年	1500万元	未公开
糖护士	北京	B轮	2018年	未公开	未公开
		A轮	2015年	数千万元	创新工场、赛富投资
		天使轮	2013年	300万元	三诺生物、创新工场
糖医生	北京	PreA轮	2016年	数千万元	上海嘉稹、上海腾辉
		天使轮	2015年	1000万元	万川医疗
		种子轮	2014年	数百万元	未公开
血糖高管	北京	PreA轮	2017年	2000万元	未公开
大糖医	上海	A轮	2017年	数千万元	深圳盈信投资集团
大糖医	上海	天使轮	2014年	数百万元	825新媒体产业基金、华映资本
睿控糖	四川	A轮	2017年	数千万元	某医药上市公司产业基金
孚视医疗	上海	A轮	2018年	1000万元	千骥资本、联合资本、上海双创
控糖卫士	北京	天使轮	2018年	数百万元	未公开
控糖卫士	北京	种子轮	2015年	200万元	未公开
悦糖	北京	天使轮	2015年	数百万元	洪泰基金
睿糖	广东	PreA轮	2018年	未公开	未公开
睿糖	广东	天使轮	2016年	未公开	共进股份
糖衣机器人	上海	天使轮	2018年	未公开	原链资本
糖衣机器人	上海	种子轮	2017年	未公开	未公开

Progress on research and development in diabetes mellitus

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 16

References 37

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huijie Yang, De Li, Huiling Bai, Ming Zhang, Jun Huang, Xiaoqing Yuan. Diagnosis, treatment and genetic analysis of a case of Alstrom syndrome caused by compoud heterozygous mutation of ALMS1 [J]. Hereditas(Beijing), 2022, 44(12): 1148-1157.
[2]	Caihong He, Wanzi Jiang, Liwen Zhang, Meihua Ruan, Hongwen Zhou, Jianrong Yu. Current status and future perspectives of rare disease research [J]. Hereditas(Beijing), 2021, 43(6): 531-544.
[3]	Wanzi Jiang, Liwen Zhang, Caihong He, Meihua Ruan, Yong Ji, Jianrong Yu, Hongwen Zhou. Progress on familial hypercholesterolemia [J]. Hereditas(Beijing), 2021, 43(11): 1011-1022.
[4]	Yuzhuo Wang, Yiming Zhang, Xiaolian Dong, Xuecai Wang, Jianfu Zhu, Na Wang, Feng Jiang, Yue Chen, Qingwu Jiang, Chaowei Fu. Modification effects of T2DM-susceptible SNPs on the reduction of blood glucose in response to lifestyle interventions [J]. Hereditas(Beijing), 2020, 42(5): 483-492.
[5]	Xian Gong, Chao Zhang, Aisa Yiliyasi, Ying Shi, Xuewei Yang, Aosiman Nuersimanguli, Yaqun Guan, Shuhua Xu. A comparative analysis of genetic diversity of candidate genes associated with type 2 diabetes in worldwide populations [J]. Hereditas(Beijing), 2016, 38(6): 543-559.
[6]	Ri Wu,Chao Ma,Xiaodan Li,Huikun Duan,Yanli Ji,Yu Wang,Pingzhe Jiang,Haisong Wang,Peipei Tu,Miao Li,Ganggang Ni,Baicheng Ma,Minggang Li. Construction of yeast strains expressing long-acting glucagon-like peptide-1 (GLP-1) and their therapeutic effects on type 2 diabetes mellitus mouse model [J]. HEREDITAS(Beijing), 2015, 37(2): 183-191.
[7]	TANG Lin-Lin LIU Qiong BU Shi-Zhong XU Lei-Ting WANG Qin-Wen MAI Yi-Feng DUAN Shi-Wei. The effect of environmental factors and DNA methylation on type 2 diabetes mellitus [J]. HEREDITAS, 2013, 35(10): 1143-1152.
[8]	PU Lian-Mei, NAN Nan, YANG Ze, JIN Ze-Ning. Association between SUMO4 polymorphisms and type 2 diabetes mellitus [J]. HEREDITAS, 2012, 34(3): 315-325.
[9]	TANG Xiao-Li, DENG Li-Bin, LI Gui-Lin, LIU Shuang-Mei, LIN Jia-Ri, XIE Jin-Yan, LIU Jun, KONG Fan-Jun, LIANG Shang-Dong. Analysis of gene expression profile of peripheral ganglia in early stage type Ⅱ diabetic rats [J]. HEREDITAS, 2012, 34(2): 198-207.
[10]	WANG Ao-Xue, CHEN Xiu-Ling. Current status and industrialization of transgenic tomatoes [J]. HEREDITAS, 2011, 33(9): 962-974.
[11]	HOU Yu-Ting, LI Jin-Na, LIN Gui-Ping, LIU Ming-Yao, SUN Guo-Feng, WANG Wen-Fei, LI De-Shan. Cloning, expression and glucose regulation activity of human FGF-21 [J]. HEREDITAS, 2010, 32(6): 583-587.
[12]	CHEN Fang-Jian, YU Hong, FAN Fan, LU Jian-Xin. Mitochondrial D-Loop gene polymorphisms in the patients with type 2 diabetes mellitus [J]. HEREDITAS, 2009, 31(3): 265-272.
[13]	. Study on a new point mutation of nt7444 G→A of mitochondrial DNA in a type 2 diabetes mellitus family [J]. HEREDITAS, 2007, 29(4): 433-437.
[14]	WANG Wei, LAI Mao-De. Alternative Splicing of Insulin Receptor mRNA in Cancer and Type 2 Diabetes Mellitus: A Review [J]. HEREDITAS, 2006, 28(2): 226-230.
[15]	ZHAO Jing, JI Jing-Zhang, WANG Da-Wang, ZHANG Jie, WU Hui-Jie, LU Jian-Xin. Detecting of mtDNA Mutations at Position A3243G and G3316A in Patients with type 2 Diabetes Mellitus in Wenzhou [J]. HEREDITAS, 2006, 28(10): 1206-1212.